Eduard Porta-Pardo
Eduard Porta-Pardo
Barcelona Supercomputing Centre / Josep Carreras Research Institute
Verified email at - Homepage
Cited by
Cited by
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
The functional impact of alternative splicing in cancer
H Climente-González, E Porta-Pardo, A Godzik, E Eyras
Cell reports 20 (9), 2215-2226, 2017
Perspective on oncogenic processes at the end of the beginning of cancer genomics
L Ding, MH Bailey, E Porta-Pardo, V Thorsson, A Colaprico, D Bertrand, ...
Cell 173 (2), 305-320. e10, 2018
A pan-cancer catalogue of cancer driver protein interaction interfaces
E Porta-Pardo, L Garcia-Alonso, T Hrabe, J Dopazo, A Godzik
PLoS Comput Biol 11 (10), e1004518, 2015
e-Driver: a novel method to identify protein regions driving cancer
E Porta-Pardo, A Godzik
Bioinformatics 30 (21), 3109-3114, 2014
Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens
M Giménez-Barcons, A Casteràs, M del Pilar Armengol, E Porta, ...
The Journal of Immunology 193 (8), 3872-3879, 2014
Comparison of algorithms for the detection of cancer drivers at subgene resolution.
E Porta-Pardo, A Kamburov, D Tamborero, T Pons, D Grases, A Valencia, ...
Nature Methods, 2017
Cancer3D: understanding cancer mutations through protein structures
E Porta-Pardo, T Hrabe, A Godzik
Nucleic Acids Research, 2014
Mutation drivers of immunological responses to cancer
E Porta-Pardo, A Godzik
Cancer immunology research 4 (9), 789-798, 2016
AIRE genetic variants and predisposition to polygenic autoimmune disease: The case of Graves’ disease and a systematic literature review
R Colobran, M Giménez-Barcons, A Marín-Sánchez, E Porta-Pardo, ...
Human Immunology 77 (8), 643-651, 2016
Analysis of individual protein regions provides novel insights on cancer pharmacogenomics
E Porta-Pardo, A Godzik
PLoS computational biology 11 (1), e1004024, 2015
Cancer3D 2.0: interactive analysis of 3D patterns of cancer mutations in cancer subsets
M Sedova, M Iyer, Z Li, L Jaroszewski, KW Post, T Hrabe, E Porta-Pardo, ...
Nucleic acids research 47 (D1), D895-D899, 2019
Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
E Porta‐Pardo, A Valencia, A Godzik
FEBS letters, 2020
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
L De Mattos-Arruda, M Vazquez, F Finotello, R Lepore, E Porta, J Hundal, ...
Annals of Oncology, 2020
The consequences of variant calling decisions in secondary analyses of cancer sequencing data
C García-Prieto, FM Jimenez, A Valencia, E Porta-Pardo
BioRxiv, 2020
Germline genetic contribution to the immune landscape of cancer
RW Sayaman, M Saad, V Thorsson, W Hendrickx, J Roelands, Y Mokrab, ...
bioRxiv, 2020
Deciphering the interactions between the immune system and cancer cells to enable precision medicine
V Ruiz-Serra, E Porta-Pardo
Book of abstracts, 98-99, 2019
Mutations in BRAF Are Associated With Higher Levels of Immune Infiltrates in Microsatellite-Stable Colon Cancer
J Rubin, E Porta-Pardo
Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
A Godzik, E Porta-Pardo
US Patent App. 15/029,676, 2016
The system can't perform the operation now. Try again later.
Articles 1–20